Want to see MTNB full AI Analyst Report?
Top Page
Matinas BioPharma
(NYSE MKT:MTNB)
Select Model
Select Model
Rating:41Neutral
Price Target:
$1.50
▲(650.00% Upside)
Action:Reiterated
Date:10/20/26
Overall score is pressured primarily by weak fundamentals (no revenue, ongoing losses, negative free cash flow, and a thin equity cushion) and a strongly bearish technical trend (price far below key moving averages with negative MACD). Valuation does not provide support due to the negative P/E and lack of dividend yield data.
Positive Factors
Low Leverage
Minimal debt reduces solvency pressure and avoids substantial interest obligations while the company funds clinical development. This gives Matinas more financial flexibility than a similarly loss-making biotech with heavy leverage, although it does not eliminate its need for external capital.
Negative Factors
No Meaningful Revenue and Persistent Losses
Matinas remains pre-commercial, with no meaningful revenue to offset research and corporate expenses. Continued large losses leave the business dependent on successful development and future financing, while the absence of operating revenue limits evidence that the platform can yet support a sustainable commercial model.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt reduces solvency pressure and avoids substantial interest obligations while the company funds clinical development. This gives Matinas more financial flexibility than a similarly loss-making biotech with heavy leverage, although it does not eliminate its need for external capital.
Read all positive factors
Matinas BioPharma (MTNB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.67M
Dividend YieldN/A
Average Volume (3M)112.83K
Price to Earnings (P/E)―
Beta (1Y)2.03
Revenue GrowthN/A
EPS Growth68.91%
CountryUS
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding979,520
10 Day Avg. Volume55,300
30 Day Avg. Volume112,827
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.66
Price to Sales (P/S)0.00
P/FCF Ratio-0.46
Enterprise Value/Market Cap1.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.17
Enterprise Value/Ebitda-0.31
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Matinas BioPharma Business Overview & Revenue Model
Company Description
Matinas BioPharma Holdings, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying and advancing a range of potential therapeutic products. The company's innovative Lipid Nanocrystal (LNC) platform technology ...
Matinas BioPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 1.10M | 3.19M | 33.00K |
| Gross Profit | -107.00K | -456.00K | -972.00K | 155.00K | -13.49M | -14.55M |
| EBITDA | -6.27M | -9.89M | -19.19M | -22.00M | -20.10M | -22.50M |
| Net Income | -7.31M | -10.35M | -24.25M | -22.94M | -21.00M | -23.28M |
Balance Sheet | ||||||
| Total Assets | 3.41M | 7.21M | 12.64M | 25.10M | 78.87M | 61.33M |
| Cash, Cash Equivalents and Short-Term Investments | 761.00K | 4.00M | 7.28M | 13.76M | 28.81M | 49.62M |
| Total Debt | 6.00K | 1.35M | 2.89M | 3.56M | 4.12M | 4.70M |
| Total Liabilities | 1.61M | 2.38M | 5.05M | 5.86M | 42.23M | 8.83M |
| Stockholders Equity | 1.80M | 4.83M | 7.59M | 19.25M | 36.64M | 52.49M |
Cash Flow | ||||||
| Free Cash Flow | -6.42M | -7.01M | -15.88M | -15.50M | -20.05M | -15.48M |
| Operating Cash Flow | -6.42M | -7.01M | -15.88M | -15.28M | -19.16M | -15.22M |
| Investing Cash Flow | 335.00K | 335.00K | 9.21M | 13.24M | 4.88M | 16.77M |
| Financing Cash Flow | 121.00K | 3.39M | 9.17M | -7.00K | 79.00K | 6.96M |
Matinas BioPharma Technical Analysis
Negative
0.20
Price Trends
2.67
Negative
5.13
Negative
7.21
Negative
Market Momentum
-0.32
Positive
33.40
Neutral
13.19
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MTNB, the sentiment is Negative. The current price of 0.2 is below the 20-day moving average (MA) of 2.41, below the 50-day MA of 2.67, and below the 200-day MA of 7.21, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 33.40 is Neutral, neither overbought nor oversold. The STOCH value of 13.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTNB.
Matinas BioPharma Risk Analysis
Matinas BioPharma disclosed 59 risk factors in its most recent earnings report. Matinas BioPharma reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Matinas BioPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $4.25M | -0.25 | -41.95% | ― | ― | 99.50% | |
44 Neutral | $6.52M | -0.48 | -46.72% | ― | -99.38% | 53.42% | |
43 Neutral | $2.62M | -0.02 | -142.16% | ― | 707.02% | 70.52% | |
41 Neutral | $1.67M | -0.09 | -181.45% | ― | ― | 68.91% | |
41 Neutral | $10.29M | -0.24 | -1693.21% | ― | ― | 45.78% |
* Healthcare Sector Average
MTNB
Matinas BioPharma
1.70
-21.28
-92.60%
NCNA
Nucana
0.99
-3.34
-77.20%
ADIL
Adial Pharmaceuticals
3.92
-5.20
-57.03%
SILO
Silo Pharma
1.18
-7.36
-86.18%
APRE
Aprea Therapeutics
0.52
-0.82
-61.42%
HCWB
HCW Biologics
1.17
-21.93
-94.93%
Matinas BioPharma Corporate Events
Delistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Matinas BioPharma Implements One-for-Fifteen Reverse Stock Split
Neutral
Sep 28, 2026
On September 25, 2026, Matinas BioPharma filed a Certificate of Amendment in Delaware to implement a one-for-fifteen reverse stock split of its common stock, which became effective at 12:01 a.m. Eastern Time on September 28, 2026. Subject to NYSE ...
Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and ComplianceStock Split
Matinas BioPharma Announces One-for-Fifteen Reverse Stock Split
Neutral
Sep 16, 2026
On September 16, 2026, Matinas BioPharma announced that its Board had approved a one-for-fifteen reverse stock split of its common stock, following stockholder authorization granted at the June 23, 2025 annual meeting. The reverse split will take ...
Delistings and Listing ChangesRegulatory Filings and Compliance
Matinas BioPharma Faces NYSE American Compliance Challenges
Negative
Sep 4, 2026
On August 31, 2026, Matinas BioPharma received a notice from NYSE American that it is not in compliance with the exchange’s continued listing standards, citing stockholders’ equity of $1.8 million as of June 30, 2026 and losses in its ...
Business Operations and StrategyPrivate Placements and Financing
Matinas BioPharma Ends At-The-Market Sales Agreement
Neutral
Jul 24, 2026
Matinas BioPharma Holdings, Inc., a biopharmaceutical company that raises capital through public equity offerings, had previously established an at-the-market sales program in July 2020 with BTIG, LLC to sell up to $50 million of its common stock....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.